Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-60
SponsorCharite University, Berlin, Germany

About this trial

Electrical vs. manual stimulation: The study compares two types of acupuncture - one using mild electrical currents and one using just manual no-needle techniques in the treatment of urinary bladder disfunction.

The study focuses on women diagnosed with multiple sclerosis (MS) who also have neurogenic bladder dysfunction - a condition where the bladder doesn't work properly due to nerve damage.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female patients, aged 18-60 years, with relapsing-remitting multiple sclerosis (RRMS) and an Expanded Disability Status Scale (EDSS) score ≤ 6

Stable immunomodulatory MS therapy for at least 3 months prior to enrollment

Presence of at least 3 out of the following 6 criteria indicative of overactive bladder dysfunction: urgency, daytime urinary frequency >10 times, nocturia >1 time per night, post-void dribbling, incontinence, or delayed initiation of micturition

Participants must be willing and cognitively and linguistically capable of adhering to the study protocol, performing the study interventions, and completing the required study documentation

Disqualifiers

Acute MS relapse within the last 3 months prior to individual study entry

Planned change in immunomodulatory therapy during the study period

Current need for regular self-catheterization (more than twice per week)

Clinically relevant post-void residual volume, confirmed by ultrasound (>100 mL or >40% of pre-void volume)

Trial design

Design model

Parallel

Treatments tested in this trial

  • group 1: electrical stimulation of acupuncture points plus routine care

    Device

    The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min electrical stimulation per foot with 10Hz and an intensity up to individual tolerance level.

  • group 2: acupressure plus routine care

    Other intervention

    The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min massage per foot

Treatment groups

150 Participants
are divided into 3 treatment groups
Group A: group 1: electrical stimulation of acupuncture points plus routine careExperimental treatment 1 intervention
Group B: group 2: acupressure plus routine careExperimental treatment 1 intervention
Group C: group 3: routine care aloneNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Incontinence Questionnaire Overactive Bladder (ICIQ-OAB)

Bladder function scoring 0-16, higher values mean worse outcome

Time frame
weeks 5 and 10 after the start of the intervention

Secondary outcomes

1

Incontinence Quality of Life Measure (I-QoL)

Disease-specific quality of life, scoring 1-110 , the higher the values the better

Time frame
weeks 5 and 10 after the start of the intervention
2

Patient's Global Impression of Change (PGIC)

Subjective improvement of bladder dysfunction since start of the study, onedimenional scale with seven grades ranging from 'very much worse' to 'very much improved'

Time frame
weeks 5 and 10 after the start of the intervention
3

3-day voiding diary

Objective voiding parameters, including mean voiding frequency and average fluid intake to urine output ratio, assessing daytime urination frequency

Time frame
weeks 5 and 10 after the start of the intervention
4

100mm Visual Analogue pain Scale (VAS) for last menstruation

Pain during the most recent menstruation ranging from 0: no pain to 100: maximum pain

Time frame
at weeks 5 and 10

Other outcomes

1

rate of rescue medication

rate of use of rescue medication (e.g., anticholinergics) and self-catheterization during trial participation

Time frame
between weeks 1 and 5 and at week 10
2

rate of adverse events

the Safety of intervention will be assessed by recording the rate of adverse events and identification of adverse reactions

Time frame
from week 1 to 10

Sponsors and contacts

Click on the lead sponsor to view all of their trials.